Browse > Article

A Case Report: Limitation of Mouth Opening in Dermatomyositis  

Kim, Hye-Kyung (Department of Oral Medicine, School of Dentistry, Dankook University)
Kim, Ki-Suk (Department of Oral Medicine, School of Dentistry, Dankook University)
Kim, Mee-Eun (Department of Oral Medicine, School of Dentistry, Dankook University)
Publication Information
Journal of Oral Medicine and Pain / v.35, no.2, 2010 , pp. 155-163 More about this Journal
Abstract
Dermatomyositis (DM) is an idiopathic inflammatory connective tissue disorder and a systemic autonomic immune disease which shows a progressive muscle weakness and characteristic rash. It is identified by a characteristic rash accompanying, or more often preceding muscle weakness. Pathognomonic skin lesions are a blue-purple discoloration on the upper eyelids with edema (heliotropic rash), a flat red rash on the face and upper trunk, and erythema of the knuckles with a raised violaceous scaly eruption (Gottron's papule). The myopathy represents inflammatory and degenerative changes primarily affecting proximal muscles. DM often involves GI tract and respiratory system with as risk of 15-25% internal malignancy. It's managed with sun protection since muscle weakness as well as a rash could be aggravated by sun exposure. Systemic corticosteroid is an initial therapy and other immunosuppressive agent has been used as alternatives. Facial muscles are unaffected and masticatory muscles are rarely affected in DM. We present trismus close to muscle contracture in a patient with DM. Therefore, it needs continuous mouth-opening exercise to prevent progressive muscle contracture and to ensure normal mouth opening.
Keywords
Dermatomyositis; Opening limitation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Brennan MT, Patronas NJ, Brahim JS et al. Bilateral condylar resorption in dermatomyositis. A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:446-451.   DOI   ScienceOn
2 Villalba L, Adams EM. Update on therapy for refractory dematomyositis and polymyositis. Curr Opin Rheumatol 1996;8:544-551.   DOI   ScienceOn
3 Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000;27:1542-1545.
4 Vencovsky J, Jarosova K, Machacek S et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95-102.   DOI   ScienceOn
5 Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006;66:1245-1247.   DOI   ScienceOn
6 Spiera R, Kagen L. Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 1998;10:556-561.   DOI   ScienceOn
7 Targoff IN. Dermatomyositis and polymyositis. Curr probl Dermatol 1991;3:131-180.   DOI   ScienceOn
8 Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7 and 403-7 [two part articles].   DOI   ScienceOn
9 Mastaglia FL, Garlepp MJ, Philips BA et al. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects.
10 Marie I, Hatron PY, Hachulla E, Wallaert B, Michon -Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998;25:1336-1343.
11 Selva-O'Callaghan A, Labrador-Horillo M, Munoz- Gall X et al. polymyositis/dermatomyositisassociated lung disease: analysis of a series of 81 patients. Lupus 2005;14:534-542.   DOI   ScienceOn
12 Pautas E, Cherin P, Piette JC et al. Features of polymyositis and dermatomyositis in the eldery: a case-control study. Clin Exp Rheumatol 2000;18: 241-244.   DOI   ScienceOn
13 Peng JC, Sheem TS, Hsu MM. Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 1995;121: 1298-1301.   DOI   ScienceOn
14 Kasper et al. Harrison's principles of internal medicine. 16th ed.-vol.2. 2005. McGrow-Hill, p.2540-2545.
15 Jeffrey P. Callen, Robert L. Wortmann, Dermatomyositis. Clinics in Dermatology 2006;24:363-373.   DOI   ScienceOn
16 Marie I, Hatron PY, Hachulla E, Wallaert B, Michon -Pasturel U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol 1998;25:1336-1343.
17 Pautas E, Cherin P, Piette JC et al. Features of polymyositis and dermatomyositis in the eldery: a case-control study. Clin Exp Rheumatol 2000;18: 241-244.   DOI   ScienceOn
18 Callen JP. Dermatomyositis. Lancet 2000;355:53-57.   DOI   ScienceOn
19 Plotz PH, Rider LG, Targoff IN, Raben N, O' Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995;122:715-724.   DOI   ScienceOn
20 Cunningham JD, Lowry LD. Head and Neck manifestations of dermatomyositis-polymyositis. Otolaryngol Head Neck Surg 1985;93:673-677.
21 Cheong WK, Hughes GRV, Norris PG, Hawk JLM. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol 1994; 131:205-208.
22 Woo TR, Rasmussen J, Callen JP. Recurrent photosensitive dermatitis preceding juvenile dermatomyositis. Pediatr Dermatol 1985;2:207-212.   DOI   ScienceOn
23 Callen JP. Photodermatitis in a 6-year-old child. Arthritis Rheum 1993;36:1483-1485.   DOI   ScienceOn
24 Zuber M, John S, Pfreundschuh M, Gause A. A young woman with a photosensitive pruritic rash on her face and upper trunk. Arthritis Rheum 1996;39:1419-1422.   DOI   ScienceOn
25 Callen JP. Photosensitivity in collagen vascular diseases. Semin Cutan Med Surg 1999;18:293-296   DOI   ScienceOn
26 Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritisrheum 1993;36: 319-324.   DOI   ScienceOn
27 Wortmann RL. Idiopathic inflammatory diseases of muscle. In: Weisman ML, Weinblatt ME, Louie JS, editors. Treatment of the rheumatic diseases. PHILADELPHIA, PA: W.B. Saunders Co.; 2001.p.390-402.